Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03179930 · ClinicalTrials.gov registry record · Phase 2
Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas
A Phase 2 study of Lymphoma and Refractory, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
- 9
- Study locations
NCT03179930 is a Phase 2 study of Lymphoma and Refractory that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 47 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (90% lower). The trial reports 9 study locations across 3 states.
The verdict
NCT03179930, a Phase 2 study of Lymphoma and Refractory, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
- 9
- Study locations
Study Summary
The purpose of this study is to test any good and bad effects of the study drugs called Pembrolizumab and Entinostat when used in combination to treat lymphoma. This combination could shrink the lymphoma but it could also cause side effects. Researchers also hope to learn whether adding entinostat to pembrolizumab can be more effective for patients with lymphoma than either drug alone.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Entinostat
Study Locations (9)
New York
- Roswell Park Cancer Institute (Data Collection Only) - Buffalo
- Memorial Sloan Kettering Commack - Commack
- Memorial Sloan Kettering Westchester - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge - Basking Ridge
- Memorial Sloan Kettering Monmouth - Middletown
- Memorial Sloan Kettering Bergen - Montvale
Illinois
- Northwestern University (Data Collection Only) - Evanston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2017-06-07 |
| Est. Completion | 2026-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03179930
The ClinicalTrials.gov registry entry for NCT03179930 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (90% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03179930 reports 9 study locations spanning 3 distinct geographic areas - top geographies include New York, New Jersey, Illinois.
Frequently Asked Questions
What is clinical trial NCT03179930 about?
NCT03179930 is a clinical study titled "Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas". The purpose of this study is to test any good and bad effects of the study drugs called Pembrolizumab and Entinostat when used in combination to treat lymphoma. This combination could shrink the lymphoma but it could also cause side effects. Researchers also hope to learn whether adding entinostat t...
What is the current status of trial NCT03179930?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2017-06-07. Estimated completion is 2026-06.
What conditions does trial NCT03179930 study?
This clinical trial studies the following conditions: Lymphoma, Refractory, Relapsed.
What interventions are being tested in trial NCT03179930?
The interventions under investigation include: Pembrolizumab (DRUG), Entinostat (DRUG).
Who is sponsoring clinical trial NCT03179930?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03179930 being conducted?
This trial has 9 study locations across Illinois, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.